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described in the article by Carrel and
colleagues.1 In contrast, we were able
to document good outcomes of the
treated patients and did not find that
the Shelhigh products were associated
with ‘‘deleterious outcome.’’
Michele Musci, MD
Henryk Siniawski, MD, PhD
Roland Hetzer, MD, PhD
Department of Cardiothoracic and
Vascular Surgery
Deutsches Herzzentrum Berlin
Berlin, Germany
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FIGURE 1. Freedom from reoperation because of valve-related events after Shelhigh implantation
(n ¼ 305 patients): Deutsches Herzzentrum Berlin, February 2000 to July 2008.
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We thankDrsMusci, Siniawski, and
Hetzer for their comments regarding
our recent article entitled ‘‘Deleterious
outcome of No-React treated stentless
valved conduits following aortic root
replacement.’’1 We appreciate their
scientific approach to the problem and
congratulate the authors on their excel-
lent results obtained in patientswith ac-
tive infective endocarditis.
The authors refer to 2 of their articles
published in 20032 and 2005,3 which
both have been cited in our article. As
already said, we originally believed
that the Shelhigh aortic valve conduit
(Shelhigh, Inc, Union, NJ) was an at-
tractive alternative to homografts. We
published our preliminary experience
soon after the prosthesis was intro-
duced and showed excellent short-d Cardiovascular Surgery c May 2009term results regarding handling of the
prosthesis and postoperative hemody-
namics.4 The positive experience de-
scribed by the Berlin group was one
of the reasons we hesitated to attribute
the catastrophic outcome in several of
our patients to the prosthesis itself.
However, there are 2 major differences
in the patient population reported by
the Berlin group and ours.
First, the authors from Berlin might
have overlooked the fact that, unlike in
their series, the majority of our patients
who received the NR2000-C prosthe-
sis did not have endocarditis at the
time of the initial operation. Our pa-
tients had subfebrile temperatures
during weeks or months after elective
operations for aortic root dilation, indi-
cating that failure of the device might
have mimicked destructive endocardi-
tis. We are wondering whether Dr
Hetzer’s group is able to differentiate
between reinfection caused by a recur-
rent endocarditis and failure of the de-
vice in all of their cases.
Second, most data presented by Dr
Musci primarily focuses on the Shel-
high Stentless aortic valve and not on
the Shelhigh aortic valved conduit. In
their article published in 2005,3 they
report on 327 patients who underwent
surgical intervention for endocarditis
between 1996 and 2003. Only 4
(1.2%) patients in this group received
the NR-2000C conduit. In the latest re-
port,5 with an impressive 1077 pa-
tients, the percentage of patients who
received the Shelhigh NR-2000C con-
duit increased to 2.4%. Therefore the
total number of implanted Shelhigh
aortic valved conduits is 26 in Berlin
compared with 115 in Berne. More-
over, the authors do not provide sepa-
rate data for the NR-2000C, and
previous experiences from a joint
multicenter study showed that the
rate of echocardiographic follow-up
was very low in this institution.
The most recent case of a severe
problem with a Shelhigh conduit was
observed at Johns Hopkins University,
and the operation was performed by
Duke Cameron. The young patient
Letters to the EditorFIGURE 1. Intraoperative view of the damaged aortic valve of the Shelhigh aortic valved conduit
NR-2000C 4 years after implantation.DISTAL AXILLARYARTERY
CANNULATION CAN BE
USEFULTO ACHIEVE
ARTERIAL INFLOW IN
DESCENDING AORTIC
SURGERY
To the Editor:
I read with great interest the recent
article by Ogino and colleagues.1
These authors advocate the approach
on the distal portion of the axillary ar-
tery for cardiopulmonary bypass and
selective cerebral perfusion in arch
surgery.We routinely use the proximal
axillary artery (approached via an in-
fraclavicular incision) for arterial in-
flow in ascending aortic surgery,
especially when the aortic arch is
involved. In one case, the direct cannu-
lation of this fragile artery caused
a complete aortic dissection that
required a successful replacement of
the ascending aorta and aortic arch.
This taught us that interposition of
a side graft permits a safe perfusion
with a lesser gradient and an easier
decannulation.
Moreover, I want to suggest the use
of distal axillary artery cannulation
in the setting of descending aorticwith a transforming growth factor b
receptor mutation (TGFBR1) received
a Shelhigh aortic valved conduit 4
years ago because of aortic root dila-
tion and a bicuspid aortic valve. Two
years later, a small pseudoaneurysm
was observed below the level of the
aortic anulus and repaired through
the valve with a pericardial patch. At
that time, we were not aware of the
problems in conjunction with Shelhigh
conduits. A few weeks ago, the patient
presented with severe aortic regurgita-
tion, and echocardiographic analysis
showed signs of a partial dehiscence
of the conduit from the native aortic
anulus. Repetitive cultures were nega-
tive. At re-exploration, the Shelhigh
aortic valved conduit was more or
less completely dehiscent, and a tear
that had occurred in the left coronary
cusp was found to be the reason for se-
vere aortic insufficiency. The coronary
artery buttons were intact, and there
were no signs of infection (Figure 1).
The prosthesis was excised in toto,
and a mechanical composite graft
was implanted. Postoperative evolu-
tion was favorable.
The data presented by the Berlin
group regarding the Shelhigh stentless
valve does not necessarily contradict
our results with the Shelhigh aortic
valved conduit. We regret that the au-
thors did not comment on the dramaticThe Journacase report from Tjan and coauthors,6
the US Food and Drug Administration
recall,7 and the warning letters8,9 that
have been issued because it would
have been interesting to know how
they feel about these most unusual
circumstances. Surgical technique is
not likely to be a factor in the behavior
of these prostheses.
Thierry Carrel, MDa
Florian S. Schoenhoff, MDa
Duke Cameron, MDb
Department of Cardiovascular
Surgerya
University Hospital Berne
Berne, Switzerland
Division of Cardiac Surgeryb
The Johns Hopkins Hospital
Baltimore, Md
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